Although progression-free survival is increasingly used in clinical trials to validate cancer medicines, a new study indicates this approach is not necessarily improving patient quality of life.

An analysis of 52 articles reporting on 38 randomized clinical trials involving nearly 14,000 patients — who were suffering from 12 different forms of cancer — found no significant association between health-related quality of life and survival when the disease was not worsening. The researchers reviewed trials that were published from 2000 to 2016.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy